B cell reconstitution and the alteration of immune cell landscape in ocrelizumab-treated patients with multiple sclerosis
Meng Wang, Carolin Otto, Camila Fernández Zapata, Adeline Dehlinger, Gerardina Gallaccio, Moritz Niederschweiberer, Patrick Schindler, Desiree Kunkel, Friedemann Paul, Klemens Ruprecht, Chotima Böttcher · FENS Forum 2024
Aim: Monoclonal anti-CD20 antibody ocrelizumab primarily depletes B cells and is approved to treat multiple sclerosis (MS). Although it is known that ocrelizumab does not completely deplete B cells and B cell reconstitution can be detected in some MS patients, little is known about phenotypes of these remaining as well as repopulating B cells and whether they associate to disease outcomes and/or to changes in other immune cell types. Method: In this study, we performed comprehensive in-depth immune profiling of ocrelizumab-treated MS patients after short-term (a cohort of 31 patients) or long-
ePoster · Neuroscience